Centessa Pharmaceuticals Subsidiary, Orexia Therapeutics, and Schrödinger Announce Collaboration to Discover Novel Orexin Receptor Agonists
October 18, 2021 08:00 ET
|
Centessa Pharmaceuticals plc
~ Discovery efforts will focus on small molecules with differentiated clinical profiles to harness the broad potential of orexin agonism across different indications ~ ~ First time Schrödinger is...
Centessa Pharmaceuticals объявляет о финансовом соглашении на 300 миллионов долларов США с Oberland Capital
October 07, 2021 04:02 ET
|
Centessa Pharmaceuticals plc
БОСТОН и ЛОНДОН, Oct. 07, 2021 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc («Центесса» или «Компания») (Nasdaq: CNTA), компания клинического уровня, использующая свою инновационную...
Centessa Pharmaceuticals nombra a David Grainger, doctor en ciencias naturales y destacado empresario en el campo de la biotecnología, director de innovación
October 06, 2021 19:40 ET
|
Centessa Pharmaceuticals plc
BOSTON y LONDRES, Oct. 07, 2021 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (la «Sociedad») (Nasdaq: CNTA), una empresa en fase clínica que aprovecha su innovador modelo de negocio centrado en...
Centessa Pharmaceuticals назначает David Grainger, доктора философии, ведущего предпринимателя в области биотехнологий, главным директором по инновациям
October 06, 2021 19:40 ET
|
Centessa Pharmaceuticals plc
БОСТОН и ЛОНДОН, Oct. 07, 2021 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc («Компания») (Nasdaq: CNTA), клиническая компания, использующая свою инновационную бизнес-модель, ориентированную на...
Centessa Pharmaceuticals nomina David Grainger, PhD, un importante imprenditore nel campo delle biotecnologie, Chief Innovation Officer
October 06, 2021 19:40 ET
|
Centessa Pharmaceuticals plc
BOSTON e LONDRA, Oct. 07, 2021 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (la "Società") (Nasdaq: CNTA), un'azienda in fase clinica che sfrutta il suo innovativo modello di business incentrato...
Centessa Pharmaceuticals ernennt David Grainger, PhD, einen führenden Biotech-Unternehmer, zum Chief Innovation Officer
October 06, 2021 19:40 ET
|
Centessa Pharmaceuticals plc
BOSTON und LONDON, Oct. 07, 2021 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc („Unternehmen“) (Nasdaq: CNTA), ein Unternehmen für Forschung im klinischen Stadium, das sein innovatives,...
Centessa Pharmaceuticals nomme David Grainger, PhD, un entrepreneur de biotechnologie de premier plan, au poste de directeur de l'innovation
October 06, 2021 19:40 ET
|
Centessa Pharmaceuticals plc
BOSTON et LONDRES, 07 oct. 2021 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (la « Société ») (Nasdaq : CNTA), une société de stade clinique tirant parti de son modèle commercial innovant centré...
Centessa Pharmaceuticals benoemt David Grainger, PhD, een toonaangevende biotechondernemer, tot Chief Innovation Officer
October 06, 2021 19:40 ET
|
Centessa Pharmaceuticals plc
BOSTON en LONDON, Oct. 07, 2021 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc ("Bedrijf") (Nasdaq: CNTA), een bedrijf in klinische fases dat zijn innovatieve assetgerichte bedrijfsmodel gebruikt...
Centessa Pharmaceuticals annuncia un accordo di finanziamento da 300 milioni di dollari con Oberland Capital
October 05, 2021 15:13 ET
|
Centessa Pharmaceuticals plc
~ La nuova linea di finanziamento da 300 milioni di dollari, associata al saldo di cassa della Società al 30 giugno 2021, consente l'accesso a oltre 900 milioni di dollari per portare avanti i...
Centessa Pharmaceuticals kondigt financieringsovereenkomst van $ 300 miljoen met Oberland Capital aan
October 05, 2021 15:13 ET
|
Centessa Pharmaceuticals plc
~ Nieuwe faciliteit van $ 300 miljoen, in combinatie met het kassaldo van het bedrijf per 30 juni 2021, biedt toegang tot meer dan $ 900 miljoen om ontwikkelingsprogramma's te stimuleren en...